Kodiak Sciences rises after eye-disease drugs meet trial goals
KOD•Kodiak Sciences said its experimental drugs Zenkuda and tabirafusp-ted met the main goals of a late-stage trial in wet age-related macular degeneration. Both achieved one-year vision gains not inferior to aflibercept, and 54% of Zenkuda patients reached a six-month dosing interval.
1. Trial results
Kodiak Sciences said Zenkuda and tabirafusp-ted met the main goals of a late-stage trial in patients with wet age-related macular degeneration. Both drugs achieved vision gains at one year that were not inferior to aflibercept, the comparison treatment.
2. Dosing and safety
About 54% of Zenkuda patients reached a six-month dosing interval, potentially reducing the number of eye injections needed. Both drugs showed safety broadly consistent with aflibercept; Kodiak plans further analyses to identify which patients may benefit most from tabirafusp-ted.
3. Approval plans
Kodiak plans to seek U.S. approval for Zenkuda in the fourth quarter of 2026, using results from five successful late-stage studies across three retinal diseases. Shares rose 43.9% to $46.56 premarket.
